10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Northern Trust Corp

Northern Trust Corp trimmed its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 5.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 561,666 shares of the company’s stock after selling 31,923 shares during the period. Northern Trust Corp owned about 0.46% of 10x Genomics worth $8,066,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in TXG. Barclays PLC raised its position in shares of 10x Genomics by 11.7% during the 3rd quarter. Barclays PLC now owns 602,536 shares of the company’s stock valued at $13,605,000 after acquiring an additional 63,079 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of 10x Genomics during the 4th quarter valued at approximately $945,000. MCF Advisors LLC acquired a new stake in shares of 10x Genomics during the 4th quarter valued at approximately $92,000. Nisa Investment Advisors LLC acquired a new stake in shares of 10x Genomics during the 4th quarter valued at approximately $237,000. Finally, SG Americas Securities LLC raised its position in shares of 10x Genomics by 209.8% during the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock valued at $1,049,000 after acquiring an additional 49,468 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Stock Performance

NASDAQ:TXG opened at $9.39 on Monday. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $25.55. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -6.18 and a beta of 1.94. The business has a fifty day moving average of $8.77 and a 200-day moving average of $12.31.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The company had revenue of $154.88 million during the quarter, compared to analysts’ expectations of $131.91 million. During the same quarter in the prior year, the business posted ($0.50) earnings per share. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, equities research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Morgan Stanley dropped their price target on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. Barclays lowered their price objective on 10x Genomics from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, May 10th. Finally, Stifel Nicolaus lowered their price objective on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $16.42.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,573 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. This represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Alan Mateo acquired 40,000 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was purchased at an average price of $11.14 per share, with a total value of $445,600.00. Following the acquisition, the director now owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This trade represents a 184.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 9.39% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.